ClinicalTrials.gg
RecruitingNCT05244967ESTIMATEUpdated Apr 30, 2026

Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility

An observational study in Sexually Transmitted Infection, sponsored by University of Luebeck. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 22 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by University of Luebeck · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
533
Ages
18 Years to 22 Years
Sex
Female
01

Study summary

A longitudinal study to investigate the prevalence of sexually transmitted infections among young women and determine the role of the female genital tract microbiome in fertility

02

Conditions studied

  • Sexually Transmitted Infection
03

In context

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

This study's planned enrollment of 533 is close to the median of 578 across 93 observational studies indexed under Sexually Transmitted Diseases.

Browse Sexually Transmitted Diseases studies →

Lead sponsor

University of Luebeck is the lead sponsor of 76 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 22 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Young women aged 18-22 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-22 years

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • sterilization
  • not capable of giving
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
533 participants (estimated)
Patient registry
No

Interventions

  • Othervaginal swab

    self-sampling, vaginal swab

06

What researchers measure

Primary outcomes

  1. number of young women with STIs

    longitudinal analysis of STIs and the female genital tract microbiome

    Time frame: at enrollment

  2. monitoring of STIs and their impact on infertility

    obtain a better understanding for the emergence of infectious infertility and the impact on the pathogenicity

    Time frame: through study completion, an average of 5 years

07

Study locations

1 of 1 sites recruiting
  • Klinik für Infektiologie und Mikrobiologie
    Lübeck, Germany
    Recruiting
    • Nadja Käding · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2028, 97 months after the start.

Of 42 non-industry observational studies under Sexually Transmitted Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 97 months is above that.

Counting every sponsor, half of 48 studies reached it within 26 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 17, 2022
StartActual
Nov 11, 2020
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 30, 2029
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05244967
Lead sponsor
University of Luebeck
Responsible party
Nadja Käding (PhD, University of Luebeck) — Principal investigator
First posted
Feb 17, 2022
Start date
Nov 11, 2020
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Apr 30, 2026

Study contacts

Nadja Käding, Dr.
Contact
nadja.kaeding@uksh.de
+4945131019010

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion